荧光引导外科手术将在儿童肿瘤的术中管理中扮演关键角色。短波红外成像（SWIR）具有相对于传统近红外I（NIR-I）成像的优势，减少了组织散射和自发荧光。在此，将两种长尾发射SWIR范围的NIR-I染料（IRDye800CW和IR12）与临床级别的抗GD2单克隆抗体（Dinutuximab-beta）结合，以对比神经母细胞瘤手术的NIR-I和SWIR成像。首次构建了一种多光谱NIR-I / SWIR荧光成像设备，以允许客观地比较两种成像窗口。先在体外对结合物进行了表征。使用以已知几何和材料组成的成像标本评估了NIR-I / SWIR设备的灵敏度和深度穿透性，显示最小可检测体积约为0.9 mm³，深度穿透性可达3 mm。体内，使用NIR-I / SWIR设备进行荧光成像，显示出两种染料的高肿瘤-背景比（TBR），其中抗GD2-IR800比抗GD2-IR12明显更亮。至关重要的是，该系统使SWIR波长的TBR高于NIR-I波长，验证了SWIR成像使肿瘤边缘高对比度分界。通过将抗GD2抗体的高特异性与现有NIR-I染料的可用性和可转化性以及SWIR在深度和肿瘤信号与背景比方面的优势相结合，GD2靶向的NIR-I / SWIR引导手术可以改善神经母细胞瘤患者的治疗，值得在未来的临床试验中进行调查。

Fluorescence-guided surgery is set to play a pivotal role in the intraoperative management of pediatric tumors. Short-wave infrared imaging (SWIR) has advantages over conventional near-infrared I (NIR-I) imaging with reduced tissue scattering and autofluorescence. Here, two NIR-I dyes (IRDye800CW and IR12), with long tails emitting in the SWIR range, were conjugated with a clinical-grade anti-GD2 monoclonal antibody (Dinutuximab-beta) to compare NIR-I and SWIR imaging for neuroblastoma surgery. A first-of-its-kind multispectral NIR-I/SWIR fluorescence imaging device was constructed to allow an objective comparison between the two imaging windows. Conjugates were first characterized in vitro. Tissue-mimicking phantoms, imaging specimens of known geometric and material composition, were used to assess the sensitivity and depth penetration of the NIR-I/SWIR device, showing a minimum detectable volume of ~0.9 mm3 and depth penetration up to 3 mm. In vivo, fluorescence imaging using the NIR-I/SWIR device showed a high tumor-to-background ratio (TBR) for both dyes, with anti-GD2-IR800 being significantly brighter than anti-GD2-IR12. Crucially, the system enabled higher TBR at SWIR wavelengths than at NIR-I wavelengths, verifying SWIR imaging enables high-contrast delineation of tumor margins. This work demonstrates that by combining the high-specificity of anti-GD2 antibodies with the availability and translatability of existing NIR-I dyes, along with the advantages of SWIR in terms of depth and tumor signal-to-background ratio, GD2-targeted NIR-I/SWIR-guided surgery could improve the treatment of neuroblastoma patients, warranting investigation in future clinical trials.